Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19

Area of Science:

• Infectious Diseases
• Immunology
• Public Health

Background:

• The global spread of COVID-19 necessitates urgent identification of effective treatments.
• Convalescent plasma and hyperimmune immunoglobulin are being explored as potential therapies for COVID-19.
• A Cochrane rapid review assessed the evidence for these treatments.

Purpose of the Study:

• To highlight and contextualize the findings of a Cochrane rapid review on convalescent plasma or hyperimmune immunoglobulin for COVID-19 treatment.
• To evaluate the current evidence regarding the effectiveness and safety of convalescent plasma therapy.

Main Methods:

• The study synthesized findings from a Cochrane rapid review.
• The review included eight studies evaluating convalescent plasma or hyperimmune immunoglobulin transfusion for COVID-19.
• Evidence quality and consistency of outcomes were assessed.

Main Results:

• Limited and low-certainty evidence exists for the effectiveness and safety of convalescent plasma in treating COVID-19 patients.
• Included studies had small participant numbers, low quality, and inconsistent outcome reporting.
• Convalescent plasma may offer a potential therapeutic option, particularly for African countries.

Conclusions:

• There is a critical need for more robust research on convalescent plasma therapy for COVID-19.
• Further investigation is imperative within African contexts to determine efficacy, safety, and health system feasibility.
• Understanding practical implications for blood transfusion services is essential for regional implementation.